Trillium Therapeutics Inc
Change company Symbol lookup
Select an option...
TRIL Trillium Therapeutics Inc
CLM Cornerstone Strategic Value Fund
HRC Hill-Rom Holdings Inc
QRTEB Qurate Retail Inc
GGN GAMCO Global Gold, Natural Resources & Income Trust
GGN GAMCO Global Gold, Natural Resources & Income Trust
GFY Western Asset Variable Rate Strategic Fund Inc
GE General Electric Co
GDXJ VanEck Vectors Junior Gold Miners ETF
GDX VanEck Vectors Gold Miners ETF
Go

Health Care : Biotechnology | Small Cap Blend
Based in Canada
Company profile

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.

Closing Price
$4.51
Day's Change
0.285 (6.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.86
Day's Low
3.91
Volume
(Below Average)
Volume:
11,446,660

10-day average volume:
14,088,656
11,446,660

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.